<div id=toc></div>

# Table of Contents

- [q-bio.GN](#q-bio.GN) [Total: 2]
- [q-bio.QM](#q-bio.QM) [Total: 2]
- [cs.LG](#cs.LG) [Total: 1]


<div id='q-bio.GN'></div>

# q-bio.GN [[Back]](#toc)

### [1] [Validating Interpretability in siRNA Efficacy Prediction: A Perturbation-Based, Dataset-Aware Protocol](https://arxiv.org/abs/2602.10152)
*Zahra Khodagholi,Niloofar Yousefi*

Main category: q-bio.GN

TL;DR: 提出"预合成门"协议验证siRNA预测模型中显著性图的可靠性，发现两种失败模式，并开发生物学先验正则化器提升显著性忠实度


<details>
  <summary>Details</summary>
Motivation: 显著性图在siRNA效力预测中作为设计指导被广泛使用，但很少在指导序列编辑前验证其归因方法的可靠性，可能导致无效的设计决策

Method: 引入"预合成门"协议进行反事实敏感性忠实度测试，通过突变高显著性位置并与组成匹配的对照比较模型输出变化；开发生物学先验正则化器(BioPrior)增强显著性忠实度

Result: 跨数据集转移揭示两种失败模式：忠实但错误（显著性有效但预测失败）和反转显著性（高显著性编辑影响小于随机编辑）；在mRNA水平数据集训练的模型在荧光素酶报告数据集上崩溃；四个基准测试中19/20通过，唯一失败案例显示反转显著性；BioPrior能增强显著性忠实度但带来数据集依赖的预测权衡

Conclusion: 显著性验证是解释引导治疗设计部署前的重要实践，预合成门协议能检测显著性图的可靠性问题，避免无效的设计指导

Abstract: Saliency maps are increasingly used as \emph{design guidance} in siRNA efficacy prediction, yet attribution methods are rarely validated before motivating sequence edits. We introduce a \textbf{pre-synthesis gate}: a protocol for \emph{counterfactual sensitivity faithfulness} that tests whether mutating high-saliency positions changes model output more than composition-matched controls. Cross-dataset transfer reveals two failure modes that would otherwise go undetected: \emph{faithful-but-wrong} (saliency valid, predictions fail) and \emph{inverted saliency} (top-saliency edits less impactful than random). Strikingly, models trained on mRNA-level assays collapse on a luciferase reporter dataset, demonstrating that protocol shifts can silently invalidate deployment. Across four benchmarks, 19/20 fold instances pass; the single failure shows inverted saliency. A biology-informed regularizer (BioPrior) strengthens saliency faithfulness with modest, dataset-dependent predictive trade-offs. Our results establish saliency validation as essential pre-deployment practice for explanation-guided therapeutic design. Code is available at https://github.com/shadi97kh/BioPrior.

</details>


### [2] [STRAND: Sequence-Conditioned Transport for Single-Cell Perturbations](https://arxiv.org/abs/2602.10156)
*Boyang Fu,George Dasoulas,Sameer Gabbita,Xiang Lin,Shanghua Gao,Xiaorui Su,Soumya Ghosh,Marinka Zitnik*

Main category: q-bio.GN

TL;DR: STRAND是一个基于DNA序列的生成模型，通过编码基因组位点序列来预测单细胞转录响应，支持零样本推理并显著扩展基因组覆盖范围。


<details>
  <summary>Details</summary>
Motivation: 现有基因水平扰动模型将针对同一基因的不同基因组位点干预（如不同转录起始位点和调控元件）合并为相同表示，无法区分这些差异，限制了预测准确性。

Method: STRAND通过编码扰动位点的调控DNA序列来表示扰动，使用该表示参数化从对照到扰动细胞状态的条件传输过程，实现基于序列而非固定基因标识的预测。

Result: 在K562、Jurkat和RPE1细胞的CRISPR扰动数据集上，STRAND在低样本条件下提升判别分数达33%，在未见基因扰动基准测试中排名最佳，跨细胞系转移性能提升0.14皮尔逊相关性。

Conclusion: STRAND通过序列条件化和传输过程显著提升扰动预测性能，能够解析基因水平模型遗漏的功能性替代转录起始位点，将推理时基因组覆盖从~1.5%扩展到~95%。

Abstract: Predicting how genetic perturbations change cellular state is a core problem for building controllable models of gene regulation. Perturbations targeting the same gene can produce different transcriptional responses depending on their genomic locus, including different transcription start sites and regulatory elements. Gene-level perturbation models collapse these distinct interventions into the same representation.
  We introduce STRAND, a generative model that predicts single-cell transcriptional responses by conditioning on regulatory DNA sequence. STRAND represents a perturbation by encoding the sequence at its genomic locus and uses this representation to parameterize a conditional transport process from control to perturbed cell states. Representing perturbations by sequence, rather than by a fixed set of gene identifiers, supports zero-shot inference at loci not seen during training and expands inference-time genomic coverage from ~1.5% for gene-level single-cell foundation models to ~95% of the genome.
  We evaluate STRAND on CRISPR perturbation datasets in K562, Jurkat, and RPE1 cells. STRAND improves discrimination scores by up to 33% in low-sample regimes, achieves the best average rank on unseen gene perturbation benchmarks, and improves transfer to novel cell lines by up to 0.14 in Pearson correlation. Ablations isolate the gains to sequence conditioning and transport, and case studies show that STRAND resolves functionally alternative transcription start sites missed by gene-level models.

</details>


<div id='q-bio.QM'></div>

# q-bio.QM [[Back]](#toc)

### [3] [Beyond SMILES: Evaluating Agentic Systems for Drug Discovery](https://arxiv.org/abs/2602.10163)
*Edward Wijaya*

Main category: q-bio.QM

TL;DR: 评估6个药物发现智能体系统在15个任务类别中的泛化能力，发现5个能力差距，提出下一代框架设计需求


<details>
  <summary>Details</summary>
Motivation: 药物发现智能体系统已展示自主合成规划、文献挖掘和分子设计能力，但需要评估其泛化能力，特别是在肽疗法、体内药理学和资源受限环境等实际场景中的应用表现

Method: 评估6个框架在15个任务类别中的表现，包括肽疗法、体内药理学和资源受限设置；进行配对知识探测实验，测试4个前沿LLM对肽的理解能力

Result: 发现5个关键能力差距：不支持蛋白质语言模型或肽特异性预测、缺乏体内与计算机数据桥梁、依赖LLM推理而无ML训练或强化学习路径、假设依赖大型制药资源、单目标优化忽略安全-疗效-稳定性权衡；知识探测实验显示瓶颈是架构而非认知问题

Conclusion: 提出下一代框架的设计需求和能力矩阵，使其能在现实约束下作为计算伙伴发挥作用，需要解决当前架构限制以充分利用LLM的肽理解能力

Abstract: Agentic systems for drug discovery have demonstrated autonomous synthesis planning, literature mining, and molecular design. We ask how well they generalize. Evaluating six frameworks against 15 task classes drawn from peptide therapeutics, in vivo pharmacology, and resource-constrained settings, we find five capability gaps: no support for protein language models or peptide-specific prediction, no bridges between in vivo and in silico data, reliance on LLM inference with no pathway to ML training or reinforcement learning, assumptions tied to large-pharma resources, and single-objective optimization that ignores safety-efficacy-stability trade-offs. A paired knowledge-probing experiment suggests the bottleneck is architectural rather than epistemic: four frontier LLMs reason about peptides at levels comparable to small molecules, yet no framework exposes this capability. We propose design requirements and a capability matrix for next-generation frameworks that function as computational partners under realistic constraints.

</details>


### [4] [EVA: Towards a universal model of the immune system](https://arxiv.org/abs/2602.10168)
*Ethan Bandasack,Vincent Bouget,Apolline Bruley,Yannis Cattan,Charlotte Claye,Matthew Corney,Julien Duquesne,Karim El Kanbi,Aziz Fouché,Pierre Marschall,Francesco Strozzi*

Main category: q-bio.QM

TL;DR: EVA是首个跨物种、多模态的免疫学与炎症基础模型，整合转录组学和病理学数据，在药物研发全流程的39个任务上实现SOTA性能。


<details>
  <summary>Details</summary>
Motivation: 当前生物基础模型主要关注单细胞分辨率，且评估指标与药物研发实际任务脱节。免疫介导疾病中共享的致病机制为迁移学习提供了独特机会，需要能够捕捉多细胞相互作用复杂表型的多模态患者表征。

Method: EVA整合跨物种、平台和分辨率的转录组学数据，结合病理学数据生成统一患者表征。建立了清晰的缩放定律，证明增加模型规模和计算资源能提升预训练和下游任务性能。采用机制可解释性方法识别生物学有意义的特征。

Result: 在涵盖药物研发管线的39个任务评估套件中，EVA在零靶点疗效预测、基因功能预测、跨物种分子扰动、患者分层、治疗反应预测等所有任务类别上均达到最先进性能。发现了跨物种和技术的交织表征模式。

Conclusion: EVA作为首个跨物种多模态免疫学基础模型，为免疫介导疾病的转化研究提供了强大工具。通过开放转录组学版本，旨在加速该领域研究进展。

Abstract: The effective application of foundation models to translational research in immune-mediated diseases requires multimodal patient-level representations that can capture complex phenotypes emerging from multicellular interactions. Yet most current biological foundation models focus only on single-cell resolution and are evaluated on technical metrics often disconnected from actual drug development tasks and challenges. Here, we introduce EVA, the first cross-species, multimodal foundation model of immunology and inflammation, a therapeutic area where shared pathogenic mechanisms create unique opportunities for transfer learning. EVA harmonizes transcriptomics data across species, platforms, and resolutions, and integrates histology data to produce rich, unified patient representations. We establish clear scaling laws, demonstrating that increasing model size and compute translates to improvements in both pretraining and downstream tasks performance. We introduce a comprehensive evaluation suite of 39 tasks spanning the drug development pipeline: zero-shot target efficacy and gene function prediction for discovery, cross-species or cross-diseases molecular perturbations for preclinical development, and patient stratification with treatment response prediction or disease activity prediction for clinical trials applications. We benchmark EVA against several state-of-the-art biological foundation models and baselines on these tasks, and demonstrate state-of-the-art results on each task category. Using mechanistic interpretability, we further identify biological meaningful features, revealing intertwined representations across species and technologies. We release an open version of EVA for transcriptomics to accelerate research on immune-mediated diseases.

</details>


<div id='cs.LG'></div>

# cs.LG [[Back]](#toc)

### [5] [ICODEN: Ordinary Differential Equation Neural Networks for Interval-Censored Data](https://arxiv.org/abs/2602.10303)
*Haoling Wang,Lang Zeng,Tao Sun,Youngjoo Cho,Ying Ding*

Main category: cs.LG

TL;DR: ICODeN：一种基于常微分方程的神经网络方法，用于处理区间删失生存数据，无需比例风险假设或参数化风险函数形式，适用于高维预测变量场景。


<details>
  <summary>Details</summary>
Motivation: 区间删失生存数据中事件发生时间无法精确观测，现有方法要么依赖强模型假设（如比例风险），要么无法处理高维预测变量，限制了在生物医学高维数据中的应用。

Method: 开发ICODeN模型，通过深度神经网络建模风险函数，通过求解常微分方程获得累积风险函数。该方法不要求比例风险假设，也不预设风险函数的参数形式，支持灵活生存建模。

Result: 在模拟研究中，无论比例风险或非比例风险、线性或非线性协变量效应，ICODeN均保持良好预测准确性和稳定性。在ADNI阿尔茨海默病数据和AREDS/AREDS2年龄相关性黄斑变性数据应用中，ICODeN能有效利用数百至上千个SNPs进行预测，并支持数据驱动的亚组识别。

Conclusion: ICODeN是一个实用的假设宽松工具，适用于高维生物医学环境中区间删失生存数据的预测分析，为复杂生存数据建模提供了灵活有效的解决方案。

Abstract: Predicting time-to-event outcomes when event times are interval censored is challenging because the exact event time is unobserved. Many existing survival analysis approaches for interval-censored data rely on strong model assumptions or cannot handle high-dimensional predictors. We develop ICODEN, an ordinary differential equation-based neural network for interval-censored data that models the hazard function through deep neural networks and obtains the cumulative hazard by solving an ordinary differential equation. ICODEN does not require the proportional hazards assumption or a prespecified parametric form for the hazard function, thereby permitting flexible survival modeling. Across simulation settings with proportional or non-proportional hazards and both linear and nonlinear covariate effects, ICODEN consistently achieves satisfactory predictive accuracy and remains stable as the number of predictors increases. Applications to data from multiple phases of the Alzheimer's Disease Neuroimaging Initiative (ADNI) and to two Age-Related Eye Disease Studies (AREDS and AREDS2) for age-related macular degeneration (AMD) demonstrate ICODEN's robust prediction performance. In both applications, predicting time-to-AD or time-to-late AMD, ICODEN effectively uses hundreds to more than 1,000 SNPs and supports data-driven subgroup identification with differential progression risk profiles. These results establish ICODEN as a practical assumption-lean tool for prediction with interval-censored survival data in high-dimensional biomedical settings.

</details>
